This grant funds research to discover and optimize small molecule antiviral candidates targeting specific emerging or re-emerging viruses with epidemic potential. Projects should focus on advancing novel or existing antivirals, improving potency, selectivity, and pharmacokinetics, and contributing to clinical investigation and deployment. The scope excludes antibodies and targets viruses such as Junin, Lassa, Hendra, and others. The goal is to strengthen global preparedness and therapeutic options for viral epidemics.
Eligible applicants include legal entities established in EU member states, associated countries, and the United States. Applicants must comply with admissibility, financial, and operational capacity conditions as described in the Horizon Europe Work Programme annexes. Specific eligibility details a
